Marker molecules associated with lung tumors
The present invention relates to nucleic acids and polypeptides associated with lung cancer. The invention is more specifically related to a nucleic acids and the polypeptides transcribed thereof, the expression of which is significantly altered in association with lung cancer. The invention relates to a series of differentially spliced transcripts of the gene disclosed herein, that are associated with tumors of the respiratory tract. Furthermore the present invention provides a method for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as e.g. lung tumors.
1. A method for detecting lung adenocarcinoma, squamous cell lung carcinoma, clear cell lung carcinoma or non-small cell lung carcinoma in an individual comprising:
a. obtaining a lung tissue sample from an individual,
b. determining the level of a nucleic acid comprising a sequence that encodes the amino acid sequence of SEQ ID NO:2 in said lung tissue sample,
c. comparing the level of said nucleic acid in said lung tissue sample to the level of said nucleic acid determined in a non-cancerous lung tissue sample, and
d. determining that there is an indication of the presence of lung adenocarcinoma, squamous cell lung carcinoma, clear cell lung carcinoma or non-small cell lung carcinoma in the individual if the level of said nucleic acid is higher in the lung tissue sample from said individual than the level of said nucleic acid in the non-cancerous lung tissue sample.
2. The method according to claim 1 , wherein the level of said nucleic acid is determined using a nucleic acid probe or primer.
3. The method according to claim 2 , wherein the nucleic acid probe is detectably labeled.
4. The method according to claim 3 , wherein the label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, biotin, digoxygenin or an enzyme.
5. The method according to claim 2 , wherein the determination of the level of said nucleic acid comprises a nucleic acid amplification reaction.
6. The method according to claim 2 , wherein the determination of the level of said nucleic acid is performed by in-situ detection.
7. The method according to claim 1 , which is carried out in the course of an in vitro molecular imaging method.
8. The method according to claim 1 , wherein said nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 1.
9. A method for detecting lung adenocarcinoma, squamous cell lung carcinoma, clear cell lung carcinoma or non-small cell lung carcinoma in an individual comprising:
a. obtaining a lung tissue sample from an individual,
b. determining the level of a nucleic acid comprising a sequence that encodes the amino acid sequence of SEQ ID NO:6 in said lung tissue sample,
c. comparing the level of said nucleic acid in said lung tissue sample to the level of said nucleic acid determined in a non-cancerous lung tissue sample, and
d. determining that there is an indication of the presence of lung adenocarcinoma, squamous cell lung carcinoma, clear cell lung carcinoma or non-small cell lung in the individual if the level of said nucleic acid is higher in the lung tissue sample from said individual than the level of said nucleic acid in the non-cancerous lung tissue sample.
10. The method according to claim 9 , wherein the level of said nucleic acid is determined using a nucleic acid probe or primer.
11. The method according to claim 10 , wherein the nucleic acid probe is detectably labeled.
12. The method according to claim 11 , wherein the label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, biotin, digoxygenin or an enzyme.
13. The method according to claim 10 , wherein the determination of the level of said nucleic acid comprises a nucleic acid amplification reaction.
14. The method according to claim 10 , wherein the determination of the level of said nucleic acid is performed by in-situ detection.
15. The method according to claim 9 , which is carried out in the course of an in vitro molecular imaging method.
16. The method according to claim 9 , wherein said nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 5.